-The Hindu Business Line Generic prescription patterns, supply-chain management must for low-cost drug availability An earnest-sounding voice answers the Jan Aushadhi hotline number and assures the person calling that more stores are being planned by the Government in districts across the country. That response was to the caller’s query if there was a Jan Aushadhi (JA) store in Mumbai. As it happens, there is one in Maharashtra, but in Pune! It’s been over...
More »SEARCH RESULT
Total Matching Records found : 232
IMA asks doctors to prescribe cheapest version of drugs -Ramya Kannan
-The Hindu It was resolved that all IMA members shall write drugs with chemical or generic name in capital letters A resolution was passed at the recent working committee meeting of the Indian Medical Association (IMA) that is likely to have the direct benefit of making drugs more accessible and affordable. It was resolved that all IMA members “shall write drugs with chemical or generic name in capital letters, and the name of...
More »Indian drug cos worried about patent regime changes -PT Jyothi Datta
-The Hindu Business Line Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on...
More »Govt to sell 504 drugs under 'Jan Aushadhi' -Sushmi Dey
-The Times of India NEW DELHI: From July 1, you can walk up to a chemist and ask for a 'Jan Aushadhi' brand for your medicine, with the government set to launch its own brand to sell low cost generic medicines. The Centre will procure medicines in bulk from public as well as private drug manufacturing firms and rebrand them under 'Jan Aushadhi'. These will be sold in the retail market at...
More »More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta
-The Hindu Business Line Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month. Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application...
More »
